Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,458 total articles
Delta Air Lines (DAL) is trading at $89.24 with an enterprise value near $68.9B, EV/EBITDA ~7.4 and free cash flow of roughly $3.0B. Near-term headwinds from fuel and industry cyclicality are real, but the balance sheet, steady ROE (~14.6%), and attractive valuation create a favorable risk/reward for a long-term trade. Entry $88.00, stop $80.00, ta…
Uber reported a clean Q3: revenue and gross bookings accelerated, management gave solid Q4 guidance for gross bookings and adjusted EBITDA, and cash generation sits comfortably in the multibillion-dollar range. I view the quarter as a validation of the marketplace improvements and capital allocation discipline. This trade idea is a directional long…
CytomX (CTMX) is trading with the market assigning only modest enterprise value to its business. With a market cap of about $512M and enterprise value near $495M, the stock behaves like a low-expectations play even as Varsetatug masetecan (Varseta-M) marches toward pivotal testing and the Regeneron collaboration expands. The risk/reward favors a di…
Cushman & Wakefield (CWK) is a buy into the post-earnings momentum. Consensus expected Q3 upside, the business generates meaningful free cash flow ($249.1M), and valuation metrics (EV/EBITDA ~9.7; P/S ~0.32) leave room for re-rating if management pivots to buybacks or debt paydown. We lay out an entry at $14.80, stop at $13.00 and target at $18.00 …
Nu Holdings ($NU) has been dislocated by political noise in Brazil, but underlying operating performance and capital metrics support a bullish stance. At the current price near $12, the stock offers a compelling risk-reward for a swing trade while also providing an attractive longer-term exposure to one of the fastest-growing digital banking franch…
Freshworks is showing tangible progress turning product-led SMB traction into higher-value enterprise contracts via Freshservice and AI tooling. Recent results beat and margin improvement, plus the Torii buy and Freddy AI Agent Studio rollout, create a path to higher revenue quality and cash flow. Valuation at roughly $3.5B market cap is reasonable…
Western Midstream (WES) is trading below near-term moving averages after a modest pullback. With a $17.6B market cap, an 8%+ yield, improving analyst revisions and a forecasted uptick in revenue and EPS for Q3, we see a mid-term trade that balances income with upside to the prior 52-week high. Technicals show an oversold setup while valuation metri…
Honeywell's post-spin, automation-focused profile has led to faster backlog conversion, margin expansion and improved free cash flow guidance. At a market cap near $72.5B and a forward P/E around 10x, the risk/reward looks favorable for a long trade into 2027. Entry at $228.45, stop at $210.00, target $260.00 — plan for a long-term trade (180 tradi…
Harmonic reported a better-than-expected quarter but trimmed its forward outlook; momentum is slipping, short interest is rising and valuation leaves little margin for execution risk. I am downgrading to a neutral-to-bearish stance and recommending a mid-term short entry at $10.22 with a stop at $11.00 and a target of $8.50.
MaxLinear's AI-driven optical business is accelerating, but the stock is trading at elevated multiples and has important technical support between $55 and $60. We lay out a mid-term swing long with a clear entry at $58.00, a stop at $53.50, and a target at $78.00, and explain the fundamental and technical reasoning behind the plan.
Bright Minds (DRUG) plunged after a regulatory setback, but a strong balance sheet (including a C$309.7M cash disclosure), recent $175M equity raise, a concentrated float, and upcoming scientific visibility create a high-reward trade for disciplined longs. Entry at $19.01, stop at $15.00, target $45.00 over a 180 trading-day horizon.
Deckers (DECK) is trading at roughly $89 and a mid-teens multiple of trailing earnings. Recent results show expanding gross margins, strong international growth, and upgraded EPS guidance despite softer top-line expectations. At the current market value, modest revenue and margin improvement plus a re-rating could generate attractive returns over a…
JPMorgan Chase (JPM) is expensive on several valuation metrics, but growing payments revenue, a large buyback authorization and consistent profitability make the stock a buy for investors willing to accept moderate valuation compression. Entry at $350, target $380, stop $332. Trade horizon: long term (180 trading days).
Workday's recent slide has left its valuation stretched for short-term uncertainty but attractive versus its growth profile and cash generation. We outline a swing trade to buy WDAY at $200.00, target $235.00, stop $185.00, and hold for roughly 45 trading days as catalysts around AI, product integrations, and earnings re-acceleration play out.
Dynex Capital's Q3 book-value hit and volatile rate backdrop pushed the share price into the low end of its 52-week range. The company still pays a hefty monthly dividend ($0.17) and trades at roughly 0.9x book with stable funding and attractive mortgage spreads. I rate DX a buy for a recovery trade: entry $10.90, stop $10.10, primary target $13.50…
Diamondback's Permian-focused portfolio, strong Q3 cash generation and capital discipline underpin a long trade after the recent pullback. The stock offers upside via FCF-driven buybacks and dividend growth, with a manageable balance sheet and a valuation that looks reasonable relative to cash generation.
Sandisk presents a compelling trade setup: the stock is trading with a PEG of roughly 0.12x, a level that implies markets are pricing in virtually no growth. With NAND demand improving from data-center and AI-related workloads and inventory normalization across the channel, this is a tactical long with defined risk control. Entry at $45.00, stop at…
Total Energy Services (TES) is positioned to benefit from rising global LNG export activity. This trade idea outlines a long bias with concrete entry, target and stop levels, thesis drivers, catalysts, valuation framing and a balanced risk section.
UiPath is a profitable enterprise automation vendor trading at a reasonable multiple after recent headlines around AI competition. With ARR growth, solid free cash flow and GAAP profitability on the books, the stock looks attractive on a mid-term rebound. This trade idea lays out an entry at $13.51, a stop at $11.50 and a target of $17.00 over the …
Bloom Energy plunged after a sharp intraday reversal, but fundamentals - including raised Q4 revenue guidance to $1.35-$1.55 billion, 138% YoY revenue growth, and a multi-billion backlog tied to AI data centers - argue the move is an overreaction. This trade targets a rebound while keeping a strict stop below recent support.
American Integrity Insurance (AII) trades cheaply on several metrics — P/E ~6.55, EV/EBITDA ~2.33, and free cash flow of $163.6M — with a 3.5% yield and no net debt. That combination creates an asymmetric payoff for a long trade, but short coverage, a low current ratio and concentrated geographic risk mean downside can come quickly. This trade idea…
CNA is a mid-cap multi-line insurer with a healthy dividend yield, reasonable valuation, and stable free cash flow. Recent underwriting margin pressure and a Q3 earnings miss mean the stock is not a clearance-priced buy, but it can be a reliable portfolio cornerstone for income and modest total return if you size exposure and set a hard stop.
Ligand Pharmaceuticals is starting to show the payoff of its royalty-first model: accelerating royalty flows, a strategic acquisition of XOMA Royalty Corporation with CVR mechanics, and improving technicals. At a $6.3B market cap and with free cash flow of roughly $90.6M, the stock merits a tactical long for traders willing to accept execution and …
Gentherm (THRM) looks mispriced relative to its emerging scale and margin profile. Recent M&A, FDA-clearance wins in medical and a still-reasonable EV/EBITDA argue for a re-rating. I favor a long trade with defined entry, stop and a $42 target over the next 180 trading days.
Booking (BKNG) printed an EPS beat and a sharp post-earnings rally, but the revenue miss, tepid Q4 guidance and softer international travel argue for a measured fade. This trade idea lays out a mid-term (45 trading days) short with precise entry, stop and target, plus the catalysts and counterarguments that could flip the trade.
